AXA3359

AXA3359 is an investigational endogenous metabolic modulator (EMM) composition developed by Axcella Health (now Axcella Therapeutics). As part of Axcella's proprietary platform, AXA3359 is a multi-component mixture, likely comprising amino acids and related metabolic precursors, designed to simultaneously target multiple metabolic pathways associated with brain health and recovery. It was evaluated in a 15-day, single-blind, placebo-controlled study in Australia (ACTRN12619000193134) to assess the food safety and tolerability in healthy adults who had recently sustained a mild traumatic brain injury (concussion). The study was conducted under a food research framework rather than a traditional Investigational New Drug (IND) pathway, reflecting the candidate's status as a potential medical food or nutritional intervention.